Advertisement
Screener

NEXENTIS TECHNOLOGIES INC. (NXTS) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

NEXENTIS TECHNOLOGIES INC. Research and Development Expense

NEXENTIS TECHNOLOGIES INC. (NXTS) reported Research and Development Expense of $373.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13

  • NEXENTIS TECHNOLOGIES INC. research and development expense for the quarter ending 2026-06-30 was $373.00K, a 4044.44% increase year-over-year.
  • NEXENTIS TECHNOLOGIES INC. research and development expense for the quarter ending 2026-03-31 was $275.00K, a 1275.00% increase year-over-year.
  • NEXENTIS TECHNOLOGIES INC. research and development expense for the quarter ending 2025-12-31 was $98.00K, a 70.39% decline year-over-year.
  • NEXENTIS TECHNOLOGIES INC. research and development expense for the quarter ending 2025-09-30 was $52.00K, a 173.68% increase year-over-year.
  • NEXENTIS TECHNOLOGIES INC. research and development expense for fiscal 2025 was $179.00K, a 51.49% decline from fiscal 2024.
  • NEXENTIS TECHNOLOGIES INC. research and development expense for fiscal 2024 was $369.00K, a 80.96% decline from fiscal 2023.
  • NEXENTIS TECHNOLOGIES INC. research and development expense for fiscal 2023 was $1.94M, a 151.42% increase from fiscal 2022.
  • NEXENTIS TECHNOLOGIES INC. research and development expense for fiscal 2022 was $770.83K, a 43.09% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-06-30$373.00K
10-Q · filed 2026-08-13
$648.00K
10-Q · filed 2026-08-13
$746.00K
derived: sum of 3 quarters · filed 2026-08-13
$798.00K
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$275.00K
10-Q · filed 2026-05-14
$373.00K
derived: sum of 2 quarters · filed 2026-05-14
$425.00K
derived: sum of 3 quarters · filed 2026-05-14
$434.00K
derived: sum of 4 quarters · filed 2026-05-14
2025-12-31$98.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$150.00K
derived: sum of 2 quarters · filed 2026-03-31
$159.00K
derived: sum of 3 quarters · filed 2026-03-31
$179.00K
10-K · filed 2026-03-31
2025-09-30$52.00K
10-Q · filed 2025-11-13
$61.00K
derived: sum of 2 quarters · filed 2025-11-13
$81.00K
10-Q · filed 2025-11-13
$412.00K
derived: sum of 4 quarters · filed 2025-11-13
2025-06-30$9.00K
10-Q · filed 2025-08-14
$29.00K
10-Q · filed 2025-08-14
$360.00K
derived: sum of 3 quarters · filed 2025-08-14
$379.00K
derived: sum of 4 quarters · filed 2025-11-13
2025-03-31$20.00K
10-Q · filed 2025-05-15
$351.00K
derived: sum of 2 quarters · filed 2025-05-15
$370.00K
derived: sum of 3 quarters · filed 2025-11-13
$376.00K
derived: sum of 4 quarters · filed 2025-11-13
2024-12-31$331.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$350.00K
derived: sum of 2 quarters · filed 2025-11-13
$356.00K
derived: sum of 3 quarters · filed 2025-11-13
$369.00K
10-K · filed 2025-03-31
2024-09-30$19.00K
10-Q · filed 2025-11-13
$122.41K
10-Q · filed 2024-11-14
$25.00K
derived: sum of 2 quarters · filed 2025-11-13
$38.00K
10-Q · filed 2025-11-13
$249.97K
10-Q · filed 2024-11-14
$250.03K
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$6.00K
10-Q · filed 2025-08-14
$11.69K
10-Q · filed 2024-08-14
$19.00K
10-Q · filed 2025-08-14
$127.56K
10-Q · filed 2024-08-14
$231.03K
derived: sum of 3 quarters · filed 2025-08-14
$1.92M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$116.00K
10-Q · filed 2025-05-15
$115.87K
10-Q · filed 2024-05-15
$225.03K
derived: sum of 2 quarters · filed 2025-05-15
$1.92M
derived: sum of 3 quarters · filed 2025-05-15
$1.94M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$109.03K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$1.80M
derived: sum of 2 quarters · filed 2025-03-31
$1.82M
derived: sum of 3 quarters · filed 2025-03-31
$1.94M
10-K · filed 2025-03-31
$1.94M
10-K · filed 2024-04-01
2023-09-30$1.69M
10-Q · filed 2024-11-14
$1.71M
derived: sum of 2 quarters · filed 2024-11-14
$1.83M
10-Q · filed 2024-11-14
$2.08M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$16.86K
10-Q · filed 2024-08-14
$135.76K
10-Q · filed 2024-08-14
$385.35K
derived: sum of 3 quarters · filed 2024-08-14
$583.85K
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31$118.91K
10-Q · filed 2024-05-15
$368.50K
derived: sum of 2 quarters · filed 2024-05-15
$567.00K
derived: sum of 3 quarters · filed 2024-05-15
$680.37K
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31$249.59K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$448.09K
derived: sum of 2 quarters · filed 2024-04-01
$561.46K
derived: sum of 3 quarters · filed 2024-04-01
$770.83K
10-K · filed 2024-04-01
2022-09-30$198.50K
10-Q · filed 2023-11-14
$311.88K
derived: sum of 2 quarters · filed 2023-11-14
$521.24K
10-Q · filed 2023-11-14
$696.92K
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$113.38K
10-Q · filed 2023-08-14
$322.74K
10-Q · filed 2023-08-14
$498.42K
derived: sum of 3 quarters · filed 2023-08-14
$564.89K
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$209.36K
10-Q · filed 2023-05-15
$385.04K
derived: sum of 2 quarters · filed 2023-05-15
$451.51K
derived: sum of 3 quarters · filed 2023-05-15
$678.25K
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$175.68K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27
$242.15K
derived: sum of 2 quarters · filed 2023-03-27
$468.89K
derived: sum of 3 quarters · filed 2023-03-27
$538.68K
10-K · filed 2023-03-27
2021-09-30$66.47K
10-Q · filed 2022-11-14
$293.21K
derived: sum of 2 quarters · filed 2022-11-14
$363.00K
10-Q · filed 2022-11-14
$439.19K
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$226.74K
10-Q · filed 2022-08-15
$296.53K
10-Q · filed 2022-08-15
$372.73K
derived: sum of 3 quarters · filed 2022-08-15
$460.19K
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31$69.79K
10-Q · filed 2022-05-16
$145.98K
derived: sum of 2 quarters · filed 2022-05-16
$233.45K
derived: sum of 3 quarters · filed 2022-05-16
$329.15K
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$76.19K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$163.66K
derived: sum of 2 quarters · filed 2022-03-31
$259.36K
derived: sum of 3 quarters · filed 2022-03-31
$417.00K
10-K · filed 2022-03-31
2020-09-30$87.47K
10-Q · filed 2021-11-15
$183.17K
derived: sum of 2 quarters · filed 2021-11-15
$340.81K
10-Q · filed 2021-11-15
$585.02K
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$95.71K
10-Q · filed 2021-08-16
$253.34K
10-Q · filed 2021-08-16
$497.56K
derived: sum of 3 quarters · filed 2021-08-16
$649.96K
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31$157.64K
10-Q · filed 2021-05-18
$401.85K
derived: sum of 2 quarters · filed 2021-05-18
$554.26K
derived: sum of 3 quarters · filed 2021-05-18
$641.43K
derived: sum of 4 quarters · filed 2021-05-18
2019-12-31$244.22K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$396.62K
derived: sum of 2 quarters · filed 2021-03-29
$483.80K
derived: sum of 3 quarters · filed 2021-03-29
$615.62K
10-K · filed 2021-03-29
2019-09-30$152.40K
10-Q · filed 2020-11-12
$239.58K
derived: sum of 2 quarters · filed 2020-11-12
$371.41K
10-Q · filed 2020-11-12
2019-06-30$87.18K
10-Q · filed 2020-08-11
$219.00K
10-Q · filed 2020-08-11
2019-03-31$131.83K
10-Q · filed 2020-05-15
2018-12-31$357.08K
10-K · filed 2020-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02